CLRB

Cellectar Biosciences Inc

1.21

Oct 29 • 1:43 PM ET -0.03 (-2.42%)

Healthcare Biotechnology USA Nano NASD

Oct 27, 7:20 AMCellectar study shows >8-year durable complete response in heavily pretreated DLBCL after single dose of iopofosine I 131, reinforcing potential in B-cell malignancies

Peers: ATNM RADX AKTS MNPR TLX KPTI DRTS GTBP NBTX MRKR

| Held by: VTI VXF

Scroll to Statements

Index	-
Market Cap	11.44M
Enterprise Value	-21.02M
Income	-22.32M
Sales	0.00M
Book/sh	3.62
Cash/sh	3.60
Dividend Est.	-
Dividend TTM	-
Dividend Ex-Date	-
Dividend Gr. 3/5Y	- -
Payout	-
Employees	11
IPO	Jun 14, 2005

P/E	-
Forward P/E	-
PEG	-
P/S	-
P/B	0.33
P/C	0.34
P/FCF	-
EV/EBITDA	-
EV/Sales	-
Quick Ratio	6.66
Current Ratio	6.66
Debt/Eq	0.05
LT Debt/Eq	0.05
Option/Short	No / Yes

EPS (ttm)	-4.55
EPS next Y	-1.92
EPS next Q	-0.56
EPS this Y	70.87%
EPS next Y	21.21%
EPS next 5Y	59.25%
EPS past 3/5Y	60.46% 48.41%
Sales past 3/5Y	- -
EPS Y/Y TTM	77.68%
Sales Y/Y TTM	-
EPS Q/Q	83.27%
Sales Q/Q	-
Earnings	Aug 13 BMO
EPS/Sales Surpr.	-9.62% -

Insider Own	1.75%
Insider Trans	11.72%
Inst Own	34.87%
Inst Trans	61.91%
ROA	-88.70%
ROE	-119.57%
ROIC	-71.09%
Gross Margin	-
Oper. Margin	-
Profit Margin	-
SMA20	-8.82%
SMA50	-36.74%
SMA200	-54.26%
Trades

Shs Outstand	9.45M
Shs Float	9.29M
Short Float	2.84%
Short Ratio	3.03
Short Interest	0.26M
52W High	4.70 -74.26%
52W Low	1.12 8.04%
Volatility	7.87% 10.53%
ATR (14)	0.12
RSI (14)	30.15
Beta	0.60
Rel Volume	1.82
Avg Volume	87.03K
Volume	105,960

Perf Week	3.42%
Perf Month	-34.24%
Perf Quarter	-52.92%
Perf Half Y	-53.46%
Perf YTD	-58.98%
Perf Year	-63.88%
Perf 3Y	-98.28%
Perf 5Y	-99.53%
Perf 10Y	-99.98%
Recom	1.00
Target Price	11.50
Prev Close	1.24
Price	1.21
Change %	-2.42%

ConsensusStrong Buy

Avg. Price Target

$10.00

Implied Upside

+726.4%

Analysts4incl. previous ratings

Rating Distribution4 Buy · 0 Hold · 0 Sell

Date	Action	Analyst	Rating Change	Price Target Change	Implied Upside
May 15, 2026	Initiated	LLadenburg Thalmann	Buy	$10	+726.4%
Mar 10, 2026	Upgrade	MMaxim Group	Hold → Buy	$10	+726.4%
Dec 05, 2024	Resumed	LLadenburg Thalmann	Buy	$13	+974.4%
Jul 01, 2020	Initiated	OOppenheimer	Outperform
Jan 21, 2020	Resumed	RROTH Capital	Buy	$10	+726.4%
Sep 13, 2019	Initiated	RROTH Capital	Buy
Dec 21, 2016	Initiated	LLadenburg Thalmann	Buy	$2.70	+123.1%

Oct-27-26 07:15AM	Cellectar Biosciences Reports Case Study Highlighting Complete Response Lasting More Than Eight Years in Heavily Pretreated DLBCL Patient Treated with Iopofosine I 131 (GlobeNewswire)
Oct-15-26 07:00AM	Cellectar Biosciences Presents Compelling Efficacy Data from Phase 2b CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Relapsed/Refractory to BTK Inhibitor Therapy at the International Workshop for Waldenstrom Macroglobulinemia (GlobeNewswire)
Sep-29-26 07:30AM	Cellectar Biosciences to Present Compelling Efficacy Data from Phase 2 CLOVER WaM Subset Analysis of Iopofosine I 131 in Patients Refractory/Resistant to BTK Inhibitor Therapy at International Workshop for Waldenstrom Macroglobulinemia (GlobeNewswire)
Aug-17-26 05:02PM	Cellectar Biosciences Inc (CLRB) (Q2 2026) Earnings Call Highlights: Strong Clinical Data and ... (GuruFocus.com)
Aug-13-26 07:15AM	Cellectar Biosciences Reports Second Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
08:05AM	Loading…
Jul-30-26 08:05AM	Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 13, 2026 (GlobeNewswire)
Jul-15-26 07:30AM	Cellectar Biosciences Announces Publication of Phase 1 Study of Iopofosine I 131 in Peer-Reviewed Journal Cancers (GlobeNewswire)
Jun-01-26 08:05AM	Cellectar Biosciences to Highlight Compelling New Efficacy Data from Phase 2b CLOVER WaM Study of Iopofosine I 131 in r/r Waldenstrom Macroglobulinemia at the American Society of Clinical Oncology Annual Meeting (GlobeNewswire) -5.41%
May-14-26 07:02PM	Cellectar Biosciences Inc (CLRB) Q1 2026 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com) +8.84%
07:15AM	Cellectar Biosciences Reports First Quarter 2026 Financial Results and Provides Corporate Updates (GlobeNewswire)
May-11-26 11:45AM	Has Centene (CNC) Outpaced Other Medical Stocks This Year? (Quartz)
08:05AM	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Thursday, May 14, 2026 (GlobeNewswire)
May-05-26 10:30AM	BC-Most Active Stocks (Associated Press) +12.37%
10:21AM	Cellectar (CLRB) Phase 2b Data Shows Durable Responses in Waldenström Macroglobulinemia (InvestorsHub)
07:10AM	Cellectar Biosciences Reports Positive 12-Month Follow-Up Data from Phase 2b CLOVER WaM Study Demonstrating Durable Responses and Efficacy of Iopofosine I 131 in r/r Waldenstrom Macroglobulinemia (GlobeNewswire)
07:00AM	Loading…
07:00AM	Cellectar Biosciences Announces Oversubscribed Financing Up to $140 Million (GlobeNewswire)
Apr-21-26 10:00AM	Cellectar Biosciences Announces Subset of CLOVER WaM Clinical Trial Data Accepted for Presentation at the American Society of Clinical Oncology Conference 2026 (GlobeNewswire)
Apr-14-26 08:35AM	Cellectar Enrolls First Patient in CLR 125 Auger-Emitting Radioconjugate Phase 1b Clinical Trial Targeting Refractory Triple Negative Breast Cancer (TNBC) (GlobeNewswire) +7.66%
Mar-04-26 07:15AM	Cellectar Biosciences Reports Financial Results for Year Ended 2025 and Provides Corporate Updates (GlobeNewswire) +8.21%
Feb-25-26 08:05AM	Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Wednesday, March 4, 2026 (GlobeNewswire)
Feb-17-26 08:05AM	Cellectar Biosciences Expands Global Intellectual Property Estate (GlobeNewswire) -5.17%
Jan-09-26 08:05AM	Cellectar Biosciences to Highlight Strategic Initiatives for 2026 at Upcoming Biotech Showcase during 44th Annual JP Morgan Healthcare Conference (GlobeNewswire) -6.95%
Dec-16-25 08:05AM	Cellectar Biosciences Announces Strategic Supply Agreement with Ionetix for Actinium-225 and Astatine-211 to Advance Targeted Alpha Therapies (GlobeNewswire)
Nov-13-25 04:00PM	Cellectar Biosciences Inc (CLRB) Q3 2025 Earnings Call Highlights: Strategic Advances and ... (GuruFocus.com) -18.00%
07:20AM	Cellectar Biosciences Reports Third Quarter 2025 Financial Results and Provides Corporate Update (GlobeNewswire)
Nov-06-25 08:05AM	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Thursday, November 13, 2025 (GlobeNewswire)
Oct-27-25 08:30AM	Cellectar Biosciences Receives Rare Pediatric Disease Designation from U.S. Food and Drug Administration for Iopofosine I 131 in Relapsed or Refractory Pediatric High-Grade Glioma (GlobeNewswire) -10.25%
Oct-14-25 08:30AM	Cellectar Biosciences Presented Promising Preclinical Data in Poster Presentation at the American Association for Cancer Research (AACR) Special Conference on Pancreatic Cancer Research (GlobeNewswire)
Oct-07-25 08:30AM	Cellectar Biosciences, Inc. Enters Into Agreements to Raise $5.8 Million (GlobeNewswire) -16.86%
Oct-06-25 07:00AM	Cellectar Biosciences Announces European Medicines Agency (EMA) Confirms Eligibility to File for Conditional Marketing Authorization (CMA) for Iopofosine I 131 as a Treatment for Refractory (post-BTKi) Waldenstrom Macroglobulinemia (WM) (GlobeNewswire) +6.75%
08:30AM	Loading…
Sep-30-25 08:30AM	Cellectar Biosciences Presented Compelling Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer (GlobeNewswire)
Sep-24-25 08:30AM	Cellectar and Evestia Clinical Announce Partnership to Support Auger-Emitting Radiopharmaceutical Clinical Trial in Triple-Negative Breast Cancer (TNBC) (GlobeNewswire) +11.15%
Sep-11-25 08:05AM	Cellectar Biosciences and ITM Enter Supply Agreement for GMP-Grade Actinium-225 (GlobeNewswire) +5.60%
Sep-09-25 08:05AM	Cellectar Biosciences to Participate at Oppenheimer 3rd Annual Targeted Radiopharmaceutical Therapies in Oncology Summit (GlobeNewswire) +5.17%
Sep-05-25 08:45AM	Cellectar Biosciences to Participate in Multiple Upcoming Medical Meetings and Industry Conferences in September (GlobeNewswire)
Sep-03-25 08:05AM	Cellectar Biosciences to Present Data in Poster Presentation at the American Association for Cancer Research Special Conference on Advances in Pancreatic Cancer Research (GlobeNewswire)
Sep-02-25 09:30AM	Breakthrough Cancer Therapies Fuel Regulatory Momentum as Global Market Expands (PR Newswire)
Aug-27-25 08:05AM	Cellectar Biosciences to Present Data in Oral Session and Panel Discussions at the American Association for Cancer Research Special Conference on Discovery and Innovation in Pediatric Cancer (GlobeNewswire)
Aug-14-25 07:19AM	Cellectar Biosciences Reports Second Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire)
Aug-07-25 08:05AM	Cellectar Biosciences to Report Second Quarter Financial Results and Host a Conference Call on Thursday, August 14, 2025 (GlobeNewswire)
Jul-15-25 12:00PM	All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy (Zacks)
Jul-02-25 04:15PM	Cellectar Biosciences Announces Closing of $6.9 Million Underwritten Public Offering, including Full Exercise of Over-Allotment Option (GlobeNewswire)
Jul-01-25 09:25AM	Cellectar Biosciences Announces Pricing of $6 Million Underwritten Public Offering (GlobeNewswire) -31.65%
Jun-30-25 11:02AM	Oncology Innovation Just Hit a Turning Point -- Here's What to Watch (PR Newswire) -10.00%
Jun-26-25 08:05AM	Cellectar Biosciences and U.S.-based Nusano Enter Into Multi-Isotope Supply Agreement (GlobeNewswire) -7.05%
Jun-24-25 08:30AM	Cellectar Biosciences Submits Phase 1b Clinical Trial Protocol to US Food and Drug Administration for CLR 125 to Treat Triple-Negative Breast Cancer (TNBC) (GlobeNewswire) +8.57%
Jun-18-25 04:30PM	Cellectar Biosciences Announces One-for-Thirty Reverse Stock Split (GlobeNewswire) -20.16%
Jun-11-25 08:05AM	Cellectar Biosciences Provides Update on CLOVER-2 Phase 1 Clinical Trial of Iopofosine I 131 in Pediatric Patients with Relapsed/Refractory High-Grade Glioma (GlobeNewswire) +16.64%
Jun-05-25 09:40AM	Are Medical Stocks Lagging Anixa Biosciences (ANIX) This Year? (Zacks) -11.61%
09:00AM	Cellectar Biosciences Enters into Common Stock Agreements to Raise $2.5 Million Priced at Market Under Nasdaq Rules (GlobeNewswire)
Jun-04-25 12:35PM	What's Behind Cellectar Biosciences' Stock Surge? FDA Update Explained (Benzinga) +66.32%
08:05AM	Cellectar Granted U.S. FDA Breakthrough Therapy Designation for Iopofosine I 131 in Waldenstrom Macroglobulinemia (WM) (GlobeNewswire)
May-22-25 09:36AM	Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies (Zacks)
May-21-25 11:37AM	4 Medical Product Stocks to Watch From a Challenging Industry (Zacks) -5.68%
May-14-25 03:30AM	Q1 2025 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:07AM	Cellectar Biosciences Inc (CLRB) Q1 2025 Earnings Call Highlights: Strategic Advances Amid ... (GuruFocus.com)
May-13-25 07:05AM	Cellectar Biosciences Reports First Quarter 2025 Financial Results and Provides a Corporate Update (GlobeNewswire) -9.13%
May-07-25 08:05AM	Cellectar Biosciences to Report First Quarter Financial Results and Host a Conference Call on Tuesday, May 13, 2025 (GlobeNewswire)
Apr-30-25 08:05AM	Cellectar Announces Plan to Explore Strategic Alternatives (GlobeNewswire) -13.54%
Apr-17-25 08:52AM	4 Medical Product Stocks to Buy From a Challenging Industry (Zacks) +5.58%
Mar-18-25 09:40AM	Is Cellectar Biosciences (CLRB) Stock Outpacing Its Medical Peers This Year? (Zacks) +11.97%
Mar-14-25 03:04AM	Cellectar Biosciences Inc (CLRB) Q4 2024 Earnings Call Highlights: Strategic Restructuring and ... (GuruFocus.com) +5.34%
Mar-13-25 11:43PM	Q4 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.37%
07:05AM	Cellectar Biosciences Reports Financial Results for Year Ended 2024 and Provides a Corporate Update (GlobeNewswire)
Mar-11-25 08:05AM	Cellectar Biosciences to Present at the 37th Annual Roth Conference (GlobeNewswire)
Mar-05-25 08:05AM	Cellectar Biosciences to Report Full Year Financial Results and Host a Conference Call on Thursday, March 13, 2025 (GlobeNewswire) +6.56%
Feb-05-25 08:05AM	Cellectar Biosciences to Present at the Oppenheimer 35th Annual Healthcare Life Sciences Conference (GlobeNewswire)
Jan-12-25 06:00PM	Cellectar Biosciences to Highlight 2025 Strategic Initiatives at Upcoming Biotech Showcase during the JP Morgan Healthcare Conference (GlobeNewswire)
Dec-11-24 11:25AM	Cellectar Biosciences Stock Plunges As Cancer-Focused Cancer Firm Pursues Strategic Options (Benzinga) -76.16%
Dec-10-24 05:00PM	Cellectar Biosciences Provides Strategic Update on Clinical Development, Pipeline Programs and Corporate Restructuring (GlobeNewswire) -5.19%
Nov-21-24 08:00AM	NorthStar Medical Radioisotopes Executes Supply Agreement With Cellectar Biosciences for Therapeutic Radioisotope Actinium-225 (Ac-225) (Business Wire)
Nov-19-24 01:39AM	Q3 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -9.04%
Nov-18-24 07:05AM	Cellectar Biosciences Reports Financial Results for Q3 2024 and Provides a Corporate Update (GlobeNewswire)
Nov-14-24 08:05AM	Cellectar Biosciences and NorthStar Medical Radioisotopes Announce Partnership for Supply of Actinium-225 (GlobeNewswire)
Nov-12-24 08:05AM	Cellectar Biosciences and SpectronRx Partner to Manufacture Novel Phospholipid Radioconjugate for the Treatment of Cancer (GlobeNewswire)
Nov-11-24 04:05PM	Cellectar Biosciences to Report Third Quarter Financial Results and Host a Conference Call on Monday, November 18, 2024 (GlobeNewswire)
Nov-07-24 06:40AM	Cellectar Selected to Present New Data from Phase 2 CLOVER-WaM Study in Oral Session at ASH 2024 (GlobeNewswire)
Nov-01-24 05:00PM	Cellectar Biosciences Announces Compliance Regarding Filing of Form 10-Q (GlobeNewswire)
Aug-26-24 06:40AM	Iopofosine I 131 Featured in Two Separate Presentations at 12th International Workshop on Waldenstrom's Macroglobulinemia (GlobeNewswire)
Aug-23-24 05:00PM	Cellectar to Restate Previously Issued Financial Statements Company Announces Receipt of Expected Delinquency Notification Letter from Nasdaq (GlobeNewswire)
Aug-13-24 06:40AM	Cellectar Biosciences Reports Financial Results for Q2 2024 and Provides a Corporate Update (GlobeNewswire) +8.60%
Aug-08-24 05:15PM	UPDATE -- Cellectar Biosciences to Announce Second Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 (GlobeNewswire)
04:05PM	Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, August 13, 2024 (GlobeNewswire)
Jul-23-24 06:40AM	Cellectar Biosciences' Iopofosine I 131 Exceeds Primary Endpoint in Waldenstrom's Macroglobulinemia Pivotal Study with 78% of Major Response Patients Remaining Progression Free at 18 Months (GlobeNewswire) -18.54%
Jul-22-24 06:40AM	Cellectar Biosciences Announces Exercise of Tranche B Warrants and Purchase of New Warrants for Approximately $19.4 million with the Potential to Raise Up to an Additional $73.3 Million (GlobeNewswire) +19.84%
Jun-27-24 06:40AM	Cellectar Biosciences to Host Key Opinion Leader Event to Review the Full Results from Its CLOVER WaM Pivotal Trial and Waldenstrom's Macroglobulinemia Market Landscape (GlobeNewswire) -19.38%
May-29-24 06:40AM	Cellectar Biosciences and City of Hope Cancer Center Enter Collaboration to Evaluate Iopofosine I 131 in Mycosis Fungoides (GlobeNewswire)
May-15-24 08:18AM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q1 2024 Earnings Call Transcript (Insider Monkey) +5.66%
03:43AM	Q1 2024 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents)
03:02AM	Cellectar Biosciences Inc (CLRB) Q1 2024 Earnings Call Transcript Highlights: Strategic ... (GuruFocus.com)
May-14-24 10:53AM	CLRB Stock Earnings: Cellectar Biosciences Misses EPS for Q1 2024 (InvestorPlace)
06:40AM	Cellectar Biosciences Reports Financial Results for Q1 2024 and Provides a Corporate Update (GlobeNewswire)
May-08-24 06:40AM	Cellectar Biosciences to Present at the Guggenheim Healthcare Talks Radiopharmaceuticals Day (GlobeNewswire)
May-07-24 06:40AM	Cellectar Biosciences to Announce First Quarter Financial Results and Host a Conference Call on Tuesday, May 14, 2024 (GlobeNewswire)
Mar-28-24 10:33AM	Cellectar Biosciences, Inc. (NASDAQ:CLRB) Q4 2023 Earnings Call Transcript (Insider Monkey) +9.49%
Mar-27-24 10:09PM	Q4 2023 Cellectar Biosciences Inc Earnings Call (Thomson Reuters StreetEvents) -5.58%
10:53AM	CLRB Stock Earnings: Cellectar Biosciences Beats EPS for Q4 2023 (InvestorPlace)
06:40AM	Cellectar Biosciences Reports Financial Results for Year Ended 2023 and Provides a Corporate Update (GlobeNewswire)

Show Previous News

Insider Trading	Relationship	Date	Transaction	Cost	#Shares	Value ($)	#Shares Total	SEC Form 4
Longcor Jarrod	Chief Operating Officer	May 07 '26	Buy	2.88	8,680	24,998	20,451	May 11 08:07 PM
CARUSO JAMES V	Chief Executive Officer	May 07 '26	Buy	2.88	8,680	24,998	20,318	May 11 08:05 PM
NEIS JOHN	Director	Dec 12 '25	Sale	3.70	198	732	10	Dec 16 06:00 PM

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

PresidentMr. James V. Caruso

VPMr. Chad J. Kolean CPA

Chief Operating OfficerMr. Jarrod Longcor

open in yahoo | open in reuters | open in marketwatch | open in google | open in EDGAR

CLRB

Cellectar Biosciences Inc

Upgrade your Finviz experience